Morgan Stanley
BLRX

Morgan Stanley’s BioLineRX BLRX Stock Holding History

Morgan Stanley’s Portfolio BLRX Stock Details BLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-100
Closed -$230 – 8434
2026
Q1 		$230 Hold
100
– – ﹤0.01% 7686
2025
Q4 		$277 Sell
100
-5,853
-98% -$20.2K ﹤0.01% 7596
2025
Q3 		$22.5K Buy
5,953
+4,410
+286% +$17.7K ﹤0.01% 6655
2025
Q2 		$7.05K Sell
1,543
-701
-31% -$2.59K ﹤0.01% 6943
2025
Q1 		$6.64K Buy
2,244
+266
+13% +$1.07K ﹤0.01% 6918
2024
Q4 		$16.9K Sell
1,978
-2,960
-60% -$43.7K ﹤0.01% 6621
2024
Q3 		$106K Buy
4,938
+3,227
+189% +$88.6K ﹤0.01% 5984
2024
Q2 		$39K Sell
1,711
-5,573
-77% -$150K ﹤0.01% 6247
2024
Q1 		$326K Sell
7,284
-4,629
-39% -$232K ﹤0.01% 5518
2023
Q4 		$748K Buy
11,913
+7,519
+171% +$465K ﹤0.01% 5440
2023
Q3 		$320K Sell
4,394
-2,130
-33% -$143K ﹤0.01% 5368
2023
Q2 		$416K Buy
6,524
+101
+2% +$5.59K ﹤0.01% 5303
2023
Q1 		$228K Buy
6,423
+99
+2% +$2.6K ﹤0.01% 5658
2022
Q4 		$149K Sell
6,324
-240
-4% -$7.14K ﹤0.01% 5790
2022
Q3 		$243K Buy
6,564
+259
+4% +$14.8K ﹤0.01% 5635
2022
Q2 		$323K Sell
6,305
-483
-7% -$26.9K ﹤0.01% 5643
2022
Q1 		$464K Buy
6,788
+284
+4% +$19.8K ﹤0.01% 5446
2021
Q4 		$531K Buy
6,504
+501
+8% +$52.2K ﹤0.01% 5507
2021
Q3 		$660K Buy
6,003
+332
+6% +$39.4K ﹤0.01% 5329
2021
Q2 		$637K Sell
5,671
-4,289
-43% -$504K ﹤0.01% 5375
2021
Q1 		$1.11M Sell
9,960
-8,345
-46% -$1M ﹤0.01% 4655
2020
Q4 		$1.84M Sell
18,305
-903
-5% -$78.9K ﹤0.01% 4230
2020
Q3 		$1.26M Buy
19,208
+5,080
+36% +$384K ﹤0.01% 4039
2020
Q2 		$966K Buy
14,128
+5,530
+64% +$377K ﹤0.01% 4205
2020
Q1 		$457K Buy
8,598
+2,198
+34% +$174K ﹤0.01% 4431
2019
Q4 		$576K Buy
6,400
+2,765
+76% +$285K ﹤0.01% 4848
2019
Q3 		$384K Buy
3,635
+1,265
+53% +$175K ﹤0.01% 4810
2019
Q2 		$519K Buy
2,370
+797
+51% +$179K ﹤0.01% 4590
2019
Q1 		$406K Sell
1,573
-66
-4% -$19.2K ﹤0.01% 4678
2018
Q4 		$430K Buy
1,639
+37
+2% +$17.8K ﹤0.01% 4881
2018
Q3 		$1.03M Sell
1,602
-83
-5% -$45.7K ﹤0.01% 4513
2018
Q2 		$900K Sell
1,685
-194
-10% -$103K ﹤0.01% 4692
2018
Q1 		$981K Buy
1,879
+138
+8% +$84.6K ﹤0.01% 4555
2017
Q4 		$1.14M Buy
1,741
+233
+15% +$153K ﹤0.01% 4451
2017
Q3 		$1.01M Buy
1,508
+167
+12% +$104K ﹤0.01% 4418
2017
Q2 		$680K Buy
1,341
+62
+5% +$31.9K ﹤0.01% 4621
2017
Q1 		$737K Buy
1,279
+252
+25% +$162K ﹤0.01% 4599
2016
Q4 		$567K Buy
1,027
+108
+12% +$67.1K ﹤0.01% 4864
2016
Q3 		$634K Buy
919
+112
+14% +$59.7K ﹤0.01% 4373
2016
Q2 		$387K Buy
807
+86
+12% +$48.1K ﹤0.01% 4579
2016
Q1 		$441K Sell
721
-41
-5% -$25.8K ﹤0.01% 4527
2015
Q4 		$594K Sell
762
-122
-14% -$101K ﹤0.01% 4410
2015
Q3 		$812K Sell
884
-30
-3% -$32K ﹤0.01% 4280
2015
Q2 		$1.46M Buy
914
+342
+60% +$424K ﹤0.01% 3913
2015
Q1 		$725K Buy
572
+527
+1,171% +$649K ﹤0.01% 4371
2014
Q4 		$44K Buy
45
+28
+165% +$24.3K ﹤0.01% 5847
2014
Q3 		$16K Hold
17
– – ﹤0.01% 6075
2014
Q2 		$21K Buy
17
+1
+6% +$1.25K ﹤0.01% 6014
2014
Q1 		$21K Buy
+16
New +$26.3K ﹤0.01% 5951

Other funds holding BLRX

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
BCV
Banque Cantonale Vaudoise Lausanne, Switzerland $722M AUM 30.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $33.6B AUM 31.03% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
DB
Danske Bank Copenhagen K, Denmark $50.6B AUM 42.84% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley's BLRX Position: Q2 2026 in Review

Morgan Stanley sold out of BioLineRX (BLRX) in Q2 2026, closing a stake of 100 shares — an estimated $230 sold.

Morgan Stanley first reported a position in BLRX in Q1 2014 and held it in 49 quarters. The position peaked at $1.84M in Q4 2020. 9 funds tracked by Wall St. Rank hold BLRX as of Q2 2026.

  • Morgan Stanley reported no remaining BioLineRX position as of Q2 2026 after selling out during the quarter.
  • Morgan Stanley sold 100 BioLineRX shares in Q2 2026, an estimated $230.
  • Morgan Stanley first reported a position in BioLineRX in Q1 2014 and held it in 49 quarters.
  • Morgan Stanley's BioLineRX position peaked at $1.84M in Q4 2020.
  • 9 funds tracked by Wall St. Rank held BioLineRX as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.